MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced the expansion of the ZUPREVO® (tildipirosin) label following approval from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines.
The label for ZUPREVO® (tildiprosin), a broad spectrum antibiotic for the treatment of Swine Respiratory Disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis, will now include metaphylactic use which allows clinically-healthy (but presumably infected) or susceptible animals in close contact with diseased animals to be treated to reduce the risk for developing clinical disease. In addition, age restrictions have been removed, allowing ZUPREVO to now be used in piglets of all ages.
“ZUPREVO is an important tool in the fight against SRD, offering long-acting protection against four major pathogens associated with this disease with just one injection,” said Olivia Azlor, MSD Animal Health. “We are pleased to announce these new label changes, which will help veterinarians and producers extend their protection against these costly diseases by reducing the risk for disease spread, and applying earlier treatment to avoid bigger problems and losses.”
SRD often comes along with reduced feed efficiency and growth, making it a major economic concern in pig farms around the world. A number of factors can contribute to SRD, and it seldom results from only one pathogen. Strict management policies and monitoring must be implemented to control the disease and avoid spread of pathogens within herds.